Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance.
Toguchi H·The Journal of international medical research
Leuprorelin acetate, a highly potent luteinizing hormone releasing hormone agonist, was originally launched in the USA to be administered once daily by self-injection for the treatment of metastatic prostatic cancer. A once-monthly intramuscularly or subcutaneously injectable depot form of leuprorelin acetate has, subs…